SARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center.
COVID-19
SARS-CoV-2 vaccination
allergy
anaphylaxis
recommendations
vaccine
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
27 May 2021
27 May 2021
Historique:
received:
09
05
2021
revised:
25
05
2021
accepted:
25
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have been reported after SARS-CoV2 RNA vaccines. Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction. This risk is estimated at 1/1,000,000 in the context of vaccine safety surveillance programs. The COVID-19 vaccination is rolling-out vastly in different courtiers and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care. The here presented recommendations and follow-up from the French allergy community and the Montpellier WHO Collaborating Center in order to support the vaccination program and intends to support to healthcare professionals in their daily basis.
Identifiants
pubmed: 34072058
pii: vaccines9060560
doi: 10.3390/vaccines9060560
pmc: PMC8228790
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare that they do not have conflict of interests related to the contents of this article.
Références
J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1533-1540.e8
pubmed: 30557713
Crit Rev Ther Drug Carrier Syst. 1990;6(4):315-65
pubmed: 2186872
Allergy. 2014 May;69(5):559-70
pubmed: 24650345
Clin Exp Allergy. 2021 Jun;51(6):861-863
pubmed: 33825239
Semin Pediatr Infect Dis. 2002 Jul;13(3):205-14
pubmed: 12199617
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1731-1733.e3
pubmed: 33217616
Allergy. 2012 Jun;67(6):783-9
pubmed: 22519410
JAMA. 2021 Apr 20;325(15):1562-1565
pubmed: 33683290
JAMA. 2021 Mar 16;325(11):1101-1102
pubmed: 33576785
World Allergy Organ J. 2020 Oct 30;13(10):100472
pubmed: 33204386
World Allergy Organ J. 2016 Sep 16;9(1):32
pubmed: 27679682
J Allergy Clin Immunol Pract. 2020 Jul - Aug;8(7):2144-2148
pubmed: 32418622
J Allergy Clin Immunol. 2019 Sep;144(3):627-633
pubmed: 31229269
Allergy. 2021 Jun;76(6):1640-1660
pubmed: 33811364
World Allergy Organ J. 2021 Feb;14(2):100517
pubmed: 33558825
J Allergy Clin Immunol. 1985 May;75(5):578-85
pubmed: 3989142
Br J Clin Pharmacol. 2019 Dec;85(12):2694-2706
pubmed: 31472022
Allergy Asthma Immunol Res. 2016 Jul;8(4):383-8
pubmed: 27126732
Allergy. 2015 Jun;70(6):609-15
pubmed: 25736171
Allergy. 2017 May;72(5):820-826
pubmed: 27874204
N Engl J Med. 2021 Mar 11;384(10):e37
pubmed: 33567190
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2139-2144
pubmed: 33831618
Allergy. 2013 Nov;68(11):1353-61
pubmed: 24117770
Allergy. 1990 Feb;45(2):142-50
pubmed: 2316824
Vaccine. 1994 May;12(6):542-50
pubmed: 8036829
Clin Exp Allergy. 2016 Jul;46(7):907-22
pubmed: 27196817
Allergy. 2014 Apr;69(4):420-37
pubmed: 24697291